基亞生物科技股份有限公司
基亞生物科技有限公司（Medigen Biotechnology Corp.）從事新藥與疫苗研發、細胞治療、核酸檢測及醫學美容。提供 MAGICELL-NK 自然殺手細胞與 GDT T細胞療法。研發管線包括與日本及美國合作的食道癌、頭頸癌及胃癌藥物（如 OBP-301）。公司成立於 1990 年，總部位於台灣台北。
今日下跌 1.33%。該股 RSI(6) 為 55.8，處於中性區間，短線無明顯超買超賣訊號。股價站上5日、20日、120日均線，跌破60日均線。KD 指標中性（K=66.4）；MACD 柱狀體為正值，維持多方動能。 （自動產生 · 非投資建議）
| 日期 | 外資 | 投信 | 自營商 | 合計 |
|---|---|---|---|---|
| 08-11 | -19 | 0 | 0 | -19 |
| 08-10 | +20 | 0 | 0 | +20 |
| 08-07 | -18 | 0 | +2 | -17 |
| 08-06 | -329 | 0 | 0 | -329 |
| 08-05 | +267 | 0 | 0 | +267 |
| 08-04 | +73 | 0 | 0 | +73 |
| 08-03 | -31 | 0 | 0 | -31 |
| 07-31 | -76 | 0 | 0 | -76 |
| 07-30 | -60 | 0 | 0 | -60 |
| 07-29 | -45 | 0 | 0 | -45 |
| 07-28 | -52 | 0 | 0 | -52 |
| 07-27 | +79 | 0 | 0 | +79 |
| 07-24 | +3 | 0 | 0 | +3 |
| 07-23 | -32 | 0 | 0 | -32 |
| 07-22 | -1 | 0 | 0 | -1 |
| 07-21 | -71 | 0 | 0 | -71 |
| 07-20 | +24 | 0 | 0 | +24 |
| 07-17 | -126 | 0 | 0 | -126 |
| 07-16 | +68 | 0 | 0 | +68 |
| 07-15 | +97 | 0 | 0 | +97 |
| 07-14 | +57 | 0 | 0 | +57 |
| 07-13 | -276 | 0 | +2 | -276 |
| 07-09 | +223 | 0 | 0 | +223 |
| 07-08 | -3 | 0 | 0 | -3 |
| 07-07 | +439 | 0 | 0 | +439 |
| 07-06 | +176 | 0 | +10 | +177 |
| 07-03 | +338 | 0 | 0 | +338 |
| 07-02 | +6 | 0 | 0 | +6 |
| 07-01 | +206 | 0 | 0 | +206 |
| 06-30 | +146 | 0 | 0 | +146 |
| 06-29 | +132 | 0 | 0 | +132 |
| 06-26 | -141 | 0 | 0 | -141 |
| 06-25 | +35 | 0 | +2 | +35 |
| 06-24 | +132 | 0 | 0 | +132 |
| 06-23 | +155 | 0 | 0 | +155 |
| 06-22 | -87 | 0 | 0 | -87 |
| 06-18 | +98 | 0 | 0 | +98 |
| 06-17 | +39 | 0 | 0 | +39 |
| 06-16 | +37 | 0 | 0 | +37 |
| 06-15 | -196 | 0 | +2 | -196 |
| 06-12 | +54 | 0 | 0 | +54 |
| 06-11 | +26 | 0 | 0 | +26 |
| 06-10 | -512 | 0 | +57 | -517 |
| 06-09 | -32 | 0 | +10 | -27 |
| 06-08 | -24 | 0 | +4 | -23 |
| 06-05 | -123 | 0 | +2 | -124 |
| 06-04 | -137 | 0 | +4 | -137 |
| 06-03 | -4 | 0 | 0 | -4 |
| 06-02 | -102 | 0 | 0 | -102 |
| 06-01 | -49 | 0 | 0 | -49 |
| 05-29 | -80 | 0 | 0 | -80 |
| 月份 | 營收 | MoM% | YoY% |
|---|---|---|---|
| 2026/04 | 9437 萬 | -6.1% | -10.3% |
| 2026/03 | 1.00 億 | +48.4% | -67.9% |
| 2026/02 | 6771 萬 | -27.4% | -24.0% |
| 2026/01 | 9332 萬 | -1.3% | -4.0% |
| 2025/12 | 9452 萬 | +5.0% | -11.1% |
| 2025/11 | 9002 萬 | -36.7% | -17.2% |
| 2025/10 | 1.42 億 | -16.7% | +22.9% |
| 2025/09 | 1.71 億 | +54.1% | -14.4% |
| 2025/08 | 1.11 億 | -4.1% | -2.8% |
| 2025/07 | 1.15 億 | -14.8% | -6.6% |
| 2025/06 | 1.36 億 | +13.8% | +21.8% |
| 2025/05 | 1.19 億 | - | -16.2% |